Jayasundara Duleepa, Hui Ben B, Regan David G, Heywood Anita E, MacIntyre C Raina, Wood James G
School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
Vaccine. 2017 Sep 18;35(39):5228-5234. doi: 10.1016/j.vaccine.2017.08.022. Epub 2017 Aug 18.
Since licensure of hepatitis A vaccine in Australia in 1994, infection rates have declined to record lows. Cross-sectional serosurveys conducted over this period meanwhile have shown rising population immunity, particularly in young to middle-aged Australians. In this study, we performed a retrospective birth cohort analysis to estimate the contributions of infection, migration and vaccination towards increased levels of age specific hepatitis A seroprevalence in Australia. When aggregated across age, we find that two-thirds of the increase in population seropositivity (67.04%) between 1994 and 2008 was due to vaccination, just under one-third due to migration, with a negligible contribution from infection (<1%). Comparisons with other data sources reflecting vaccine uptake suggest the magnitude of this effect is realistic. We suggest that these results primarily relate to opportunistic vaccination and indicate the level of population immunity achievable through opportunistic programs providing further evidence for policy considerations around universal hepatitis A vaccine recommendations.
自1994年澳大利亚批准甲型肝炎疫苗上市以来,感染率已降至历史最低水平。与此同时,在此期间进行的横断面血清学调查显示,人群免疫力不断提高,尤其是在澳大利亚的年轻人到中年人中。在本研究中,我们进行了一项回顾性出生队列分析,以评估感染、移民和疫苗接种对澳大利亚特定年龄组甲型肝炎血清阳性率上升的贡献。按年龄汇总后,我们发现,1994年至2008年期间人群血清阳性率增加的三分之二(67.04%)是由于疫苗接种,略低于三分之一是由于移民,感染的贡献可忽略不计(<1%)。与反映疫苗接种情况的其他数据来源进行比较表明,这种影响的程度是现实的。我们认为,这些结果主要与机会性疫苗接种有关,并表明通过机会性项目可实现的人群免疫水平,为围绕普遍推荐甲型肝炎疫苗的政策考虑提供了进一步的证据。